7W3 Stock Chart & Stats
€1.47
€0.03(4.26%)
At close: 4:00 PM EST
€1.47
€0.03(4.26%)
Day’s Range― - ―
52-Week Range€0.83 - €1.61
Previous CloseN/A
Volume184.00
Average Volume (3M)40.00
Market Cap
€273.09M
Enterprise Value€2.03B
Total Cash (Recent Filing)€947.97M
Total Debt (Recent Filing)€244.38M
Price to Earnings (P/E)16.9
Beta0.27
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.40
Shares Outstanding313,389,160
10 Day Avg. Volume33
30 Day Avg. Volume40
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.51
Price to Sales (P/S)5.75
P/FCF Ratio25.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€82.67M
Bulls Say, Bears Say
Bulls Say
High Gross And Improving Net MarginsSustained ~72% gross margin and a rise to ~18.5% net margin in 2025 reflect durable product-level profitability and improving operating leverage. For a medical-device business this implies pricing power, low unit costs on consumables, and scope to fund R&D and distribution.
Modest Leverage And Larger Equity BaseA low debt-to-equity ratio (~0.17) and a rebuilt equity base enhance financial flexibility, reduce interest burden, and support capital allocation for clinical trials, market expansion, or product launches without heavy reliance on external financing.
Improved Cash Generation And FCF ConversionMaterial improvement in operating cash flow and FCF coverage (~87% of net income) indicates the business increasingly converts accounting profits to real cash, strengthening ability to self-fund growth, service obligations, and reinvest in sales and clinical support.
Bears Say
Historical Earnings And Equity VolatilityThe company experienced deep volatility historically, including negative equity and multi-year losses, signaling structural operating risks or execution challenges. Although repaired, prior capital weakness shows that results can reverse under stress, increasing long-term operational risk.
Inconsistent Cash Flows Through CyclesCash generation has been uneven with prior years of negative OCF/FCF and a recent decline in FCF growth, implying reliance on working-capital timing, tender cycles or variable procedure volumes. This unevenness can constrain steady reinvestment and make planning tougher over cycles.
Moderate Returns On Equity And Relative ProfitabilityROE of ~7.9% signals only moderate capital efficiency relative to top medical-device peers. Even with margin gains, middling returns may limit long-term shareholder upside versus competitors unless growth or asset efficiency improves materially.
Acotec Scientific Holdings Limited News
7W3 FAQ
What was Acotec Scientific Holdings Limited’s price range in the past 12 months?
Acotec Scientific Holdings Limited lowest stock price was €0.82 and its highest was €1.61 in the past 12 months.
What is Acotec Scientific Holdings Limited’s market cap?
Acotec Scientific Holdings Limited’s market cap is €273.09M.
When is Acotec Scientific Holdings Limited’s upcoming earnings report date?
Acotec Scientific Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 28 days.
How were Acotec Scientific Holdings Limited’s earnings last quarter?
Acotec Scientific Holdings Limited released its earnings results on Mar 26, 2026. The company reported €0.012 earnings per share for the quarter, beating the consensus estimate of N/A by €0.012.
Is Acotec Scientific Holdings Limited overvalued?
According to Wall Street analysts Acotec Scientific Holdings Limited’s price is currently Overvalued.
Does Acotec Scientific Holdings Limited pay dividends?
Acotec Scientific Holdings Limited does not currently pay dividends.
What is Acotec Scientific Holdings Limited’s EPS estimate?
Acotec Scientific Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acotec Scientific Holdings Limited have?
Acotec Scientific Holdings Limited has 313,389,160 shares outstanding.
What happened to Acotec Scientific Holdings Limited’s price movement after its last earnings report?
Acotec Scientific Holdings Limited reported an EPS of €0.012 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.8%.
Which hedge fund is a major shareholder of Acotec Scientific Holdings Limited?
Currently, no hedge funds are holding shares in DE:7W3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―